Literature DB >> 10323448

Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis.

V S Rajkumar1, C Sundberg, D J Abraham, K Rubin, C M Black.   

Abstract

OBJECTIVE: To determine the temporal and spatial relationship between platelet-derived growth factor beta (PDGFbeta) receptors, PDGF-AB/BB, and activated pericytes across the Raynaud's phenomenon (RP) and systemic sclerosis (SSc; scleroderma) disease spectrum.
METHODS: Monoclonal antibodies against PDGFbeta receptors, PDGF-AB/BB, and high molecular weight-melanoma-associated antigen (HMW-MAA), a marker for activated pericytes, were used to immunohistochemically analyze serial sections of skin biopsy tissue from patients with RP and from scleroderma patients. To delineate cell-specific PDGFbeta receptor expression, double immunofluorescence-stained sections were analyzed using computer-aided image analysis and confocal microscopy.
RESULTS: PDGFbeta receptor-expressing cells and HMW-MAA-expressing pericytes were found in biopsy samples from autoimmune RP patients and in both early fibrotic and early nonfibrotic scleroderma skin, but not in normal or primary RP or late-stage scleroderma skin. PDGF-AB/BB was expressed within the epidermis, at the epidermal/dermal junction, and by dermal macrophages. Analysis of juxtaposed serial sections revealed an increased frequency of receptor expression in microvessels from autoimmune RP and early scleroderma skin (P < 0.01). Double-labeling studies using confocal microscopy showed that, in vivo, PDGFbeta receptors were predominantly expressed by microvascular pericytes from both autoimmune RP and early scleroderma skin.
CONCLUSION: PDGFbeta receptors are expressed by activated microvascular pericytes in patients with autoimmune RP and in early SSc patients, but not in those with primary RP or late-stage scleroderma. These findings suggest that features of autoimmune RP are distinct from those of primary RP, and that microvascular pericytes may be an important link between chronic microvascular damage and fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323448     DOI: 10.1002/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

Review 1.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

Review 2.  Origin of fibrosing cells in systemic sclerosis.

Authors:  Sarah Ebmeier; Valerie Horsley
Journal:  Curr Opin Rheumatol       Date:  2015-11       Impact factor: 5.006

Review 3.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 4.  The pathogenesis of systemic sclerosis revisited.

Authors:  Matthias Geyer; Ulf Müller-Ladner
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 5.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 6.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

7.  Possible strategies for anti-fibrotic drug intervention in scleroderma.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-01-29       Impact factor: 5.782

Review 8.  Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate.

Authors:  Monique E Hinchcliff; Jon Lomasney; Julie A Johnson; John Varga
Journal:  Rheumatology (Oxford)       Date:  2016-06-23       Impact factor: 7.580

Review 9.  Update on juvenile systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

10.  Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

Authors:  Andrew Leask
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.